Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study

Bo Baslund; Niels Tvede; Bente Danneskiold-Samsøe; Per Larsson; Gabriel Panayi; Joergen Petersen; Lars J Petersen; Frank J M Beurskens; Janine Schuurman; Jan G J van de Winkel; Paul W H I Parren; J Alastair Gracie; Sarah Jongbloed; Foo Y Liew; Iain B McInnes

doi:10.1002/art.21249

Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study

Bo Baslund, Niels Tvede, Bente Danneskiold-Samsøe, Per Larsson, Gabriel Panayi, Joergen Petersen, Lars J Petersen, Frank J M Beurskens, Janine Schuurman, Jan G J van de Winkel, Paul W H I Parren, J Alastair Gracie, Sarah Jongbloed, Foo Y Liew, Iain B McInnes

263 Citations (Scopus)

Abstract

Interleukin-15 (IL-15) is a proinflammatory, innate response cytokine that mediates pleiotropic effector function in rheumatoid arthritis (RA) inflammatory synovitis. Our objective was to study the ability of HuMax-IL15, a human IgG1 anti-IL-15 monoclonal antibody, to neutralize exogenous and endogenous IL-15 activity in vitro and to perform a phase I-II dose-escalation trial with HuMax-IL15 in patients with active RA.

Original language	English
Journal	Arthritis & Rheumatism
Volume	52
Issue number	9
Pages (from-to)	2686-92
Number of pages	7
ISSN	0004-3591
DOIs	https://doi.org/10.1002/art.21249
Publication status	Published - 1 Sept 2005

Access to Document

10.1002/art.21249

Cite this

Baslund, B., Tvede, N., Danneskiold-Samsøe, B., Larsson, P., Panayi, G., Petersen, J., Petersen, L. J., Beurskens, F. J. M., Schuurman, J., van de Winkel, J. G. J., Parren, P. W. H. I., Gracie, J. A., Jongbloed, S., Liew, F. Y., & McInnes, I. B. (2005). Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis & Rheumatism, 52(9), 2686-92. https://doi.org/10.1002/art.21249

Baslund, B, Tvede, N, Danneskiold-Samsøe, B, Larsson, P, Panayi, G, Petersen, J, Petersen, LJ, Beurskens, FJM, Schuurman, J, van de Winkel, JGJ, Parren, PWHI, Gracie, JA, Jongbloed, S, Liew, FY & McInnes, IB 2005, 'Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study', Arthritis & Rheumatism, vol. 52, no. 9, pp. 2686-92. https://doi.org/10.1002/art.21249

@article{db4a25cb7660415183f1e604a7e2296e,

title = "Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study",

abstract = "Interleukin-15 (IL-15) is a proinflammatory, innate response cytokine that mediates pleiotropic effector function in rheumatoid arthritis (RA) inflammatory synovitis. Our objective was to study the ability of HuMax-IL15, a human IgG1 anti-IL-15 monoclonal antibody, to neutralize exogenous and endogenous IL-15 activity in vitro and to perform a phase I-II dose-escalation trial with HuMax-IL15 in patients with active RA.",

author = "Bo Baslund and Niels Tvede and Bente Danneskiold-Sams{\o}e and Per Larsson and Gabriel Panayi and Joergen Petersen and Petersen, \{Lars J\} and Beurskens, \{Frank J M\} and Janine Schuurman and \{van de Winkel\}, \{Jan G J\} and Parren, \{Paul W H I\} and Gracie, \{J Alastair\} and Sarah Jongbloed and Liew, \{Foo Y\} and McInnes, \{Iain B\}",

year = "2005",

month = sep,

day = "1",

doi = "10.1002/art.21249",

language = "English",

volume = "52",

pages = "2686--92",

journal = "Arthritis \& Rheumatism",

issn = "0004-3591",

publisher = "John Wiley \& Sons Inc.",

number = "9",

}

TY - JOUR

T1 - Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study

AU - Baslund, Bo

AU - Tvede, Niels

AU - Danneskiold-Samsøe, Bente

AU - Larsson, Per

AU - Panayi, Gabriel

AU - Petersen, Joergen

AU - Petersen, Lars J

AU - Beurskens, Frank J M

AU - Schuurman, Janine

AU - van de Winkel, Jan G J

AU - Parren, Paul W H I

AU - Gracie, J Alastair

AU - Jongbloed, Sarah

AU - Liew, Foo Y

AU - McInnes, Iain B

PY - 2005/9/1

Y1 - 2005/9/1

N2 - Interleukin-15 (IL-15) is a proinflammatory, innate response cytokine that mediates pleiotropic effector function in rheumatoid arthritis (RA) inflammatory synovitis. Our objective was to study the ability of HuMax-IL15, a human IgG1 anti-IL-15 monoclonal antibody, to neutralize exogenous and endogenous IL-15 activity in vitro and to perform a phase I-II dose-escalation trial with HuMax-IL15 in patients with active RA.

AB - Interleukin-15 (IL-15) is a proinflammatory, innate response cytokine that mediates pleiotropic effector function in rheumatoid arthritis (RA) inflammatory synovitis. Our objective was to study the ability of HuMax-IL15, a human IgG1 anti-IL-15 monoclonal antibody, to neutralize exogenous and endogenous IL-15 activity in vitro and to perform a phase I-II dose-escalation trial with HuMax-IL15 in patients with active RA.

UR - https://www.scopus.com/pages/publications/25444519432

U2 - 10.1002/art.21249

DO - 10.1002/art.21249

M3 - Journal article

C2 - 16142748

SN - 0004-3591

VL - 52

SP - 2686

EP - 2692

JO - Arthritis & Rheumatism

JF - Arthritis & Rheumatism

IS - 9

ER -

Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study

Abstract

Access to Document

Other files and links

Fingerprint

Cite this